- Research
- Open Access
Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction
- Received: 4 August 2015
- Accepted: 11 February 2016
- Published: 25 February 2016
Abstract
Background
Combination therapy with artesunate plus sulfadoxine-pyrimethamine (SP) was adopted as recommended treatment for Plasmodium falciparum infection in Afghanistan in 2003.
Methods
A series of prospective clinical studies examining the efficacy of artesunate plus sulfadoxine-pyrimethamine (AS + SP) against P. falciparum were undertaken in sentinel sites in Afghanistan from 2007 to 2014, accompanied by relevant molecular studies. The first study was a randomized trial of AS + SP versus dihydroartemisinin-piperaquine, while two subsequent studies were standard therapeutic efficacy studies of AS + SP.
Results
Three hundred and three patients were enrolled across four provinces in the north and east of the country. Curative efficacy was high in all the trials, with an adequate clinical and parasitological response (ACPR) of more than 95 % in all groups and trial stages. Genotyping for drug-resistance alleles at dhfr indicated fixation of the S108 N mutation and a prevalence of the C59R mutation of approximately 95 % across all sites. Other mutations in dhfr and dhps remained rare or absent entirely, although five isolates from the first trial carried the dhps triple mutant SGEGA haplotype. In the last study undertaken in 2012–2014 the K13 artemisinin resistance marker was examined; only two of 60 successfully sequenced samples carried a K13-propeller mutation.
Conclusions
These data confirm maintained efficacy 10 years after introduction of artesunate plus SP as combination treatment of P. falciparum in Afghanistan. The molecular data indicate that despite a substantial fall in incidence, resistance has not developed to artemisinins, or intensified to the ACT partner drug components.
Trial Registration http://www.clinicaltrials.gov/ct NCT00682578, NCT01115439 and NCT01707199
Keywords
- Malaria
- Falciparum
- Afghanistan
- Artesunate
- Sulphadoxine
- Pyrimethamine
- Dihydrofolate reductase
- Dihydropteroate synthase
- Piperaquine
- Kelch
Background
Plasmodium falciparum transmission occurs at its most northerly latitudes in Afghanistan, where the distribution of cases is determined by the physical geography of the country, malaria being confined to lower lying areas with sufficient rainfall for mosquito survival. These consist of the northern plains [1], the Jalalabad basin to the east (bordering Pakistan), and river valleys that fringe the central mountains to the west and south [2]. The central area of Afghanistan, occupied by the western end of the Hindu Kush mountain range, is relatively free of malaria [3, 4]. The incidence of clinical cases peaks in November [5]. Following falls in incidence, northern areas are now preparing for malaria elimination in line with neighbouring countries (Turkmenistan, Uzbekistan and Tajikistan).
Chloroquine-resistant P. falciparum was evident in Afghanistan and Pakistan by the 1990s [6–9] and the combination of artesunate with amodiaquine also proved to have low efficacy [7] consistent with spread of the SVMNT pfcrt haplotype [10]. However, sulfadoxine-pyrimethamine (SP) retained reasonable efficacy in eastern [7] and northern Afghanistan (Kunduz province, 2002–2003) [11], findings which suggested that AS + SP might be an efficacious therapy for falciparum malaria in the region. Combination therapy with AS + SP was adopted as recommended treatment for P. falciparum infection in a number of south Asian countries, becoming first-line treatment in Afghanistan (2003), Iran (2006), Pakistan (2007) and India (2007).
This paper describes a series of therapeutic efficacy studies undertaken to examine the efficacy of AS + SP against P. falciparum in sentinel sites in Afghanistan from 2007 to 2014, accompanied by relevant molecular studies. These confirm maintained efficacy of the combination against P. falciparum with no evidence for increase in prevalence of molecular markers of artemisinin and SP resistance.
Methods
Sites
Studies were undertaken at, or within 20 km of, four provincial control centres, two located to the north and two to the south and east of the Hindu Kush mountains. Jalalabad, capital of Nangarhar province, is a referral centre for the whole eastern region and lies adjacent to the Pakistani border where population movement in both directions takes place. The population is multi-ethnic with Pashtoon being the dominant group. The province as a whole is generally semiarid but where possible rice is cultivated. Asadabad is the capital city of Kunar province, a largely mountainous area bordering Pakistan, with which there is uncontrolled movement via unofficial borders. Taloqan is the capital of the north-east province of Takhar with a population that is mainly Tajik with significant proportions of Uzbek and Pashtoon. Rice is cultivated on the plain and malaria is a well-known health problem [12]. Maimana is the capital city of the north-west province of Faryab bordering Turkmenistan, with which there is no open border. The population is mainly Uzbek and Turkmen and the region is semi-arid.
Participants
Trial 1 was a prospective, open label, parallel group randomized trial with a 1:1 allocation ratio of AS + SP to dihydroartemisinin-piperaquine (DP) undertaken in all four centres. Trials 2 and 3 were therapeutic single-arm efficacy studies of AS + SP undertaken in Jalalabad (Nangarhar province), and Asadabad (Kunar province) respectively. In all trials eligible participants were adults and children over 6 months old presenting with symptomatic, uncomplicated, microscopically confirmed monoinfection with asexual stages of P. falciparum. Additional study inclusion criteria were the ability to swallow oral medication, ability and willingness to comply with the study protocol for the duration of the study and written informed consent (from a parent or guardian in the case of children under 18 years of age). In trial 1 there was no lower limit of asexual parasitaemia and patients with parasitemia of more than 100,000/µL were excluded. In trials 2 and 3 only patients with 500–150,000/µL asexual forms were included.
In all trials exclusion criteria included the presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO [13], mixed malaria infection, enrollment in any other investigational study in the previous month, known underlying chronic disease requiring treatment, a history of hypersensitivity reactions or contraindications to any of the study medications and pregnancy. Pregnancy was excluded via urine dipstick testing, although unmarried females over 12 years of age were also included without a urine test given the cultural sensitivity of pregnancy testing in this group. In trial 1, treatment with antimalarials in the past month was an additional exclusion criterion. In trials 2 and 3, additional exclusion criteria were severe malnutrition (defined as a child whose growth standard is below −3 z-score, has symmetrical oedema involving at least the feet or a mid-upper arm circumference < 110 mm), presence of febrile conditions due to diseases other than malaria and regular medication potentially interfering with antimalarial pharmacokinetics.
Trial methodology
Standard case record forms were used to record demographic information, details of symptoms and their duration, and previous antimalarial medications. Clinical examination findings and vital signs were documented, including axillary temperature measured with a digital thermometer. Blood samples were obtained for haemoglobin measurement and Giemsa-staining of thick and thin blood films to confirm parasite species and parasitaemia by a standard approximation method (40 × number of parasites per 200 white blood cells on the thick film). Slide examination results were considered to be negative after examination of 200 oil fields of the thick film. 20–100 µl baseline blood was collected on filter papers for subsequent confirmation of species by PCR and testing of drug resistance markers.
Interventions
For patients receiving AS + SP, each drug was dosed to the nearest half tablet, determined from a dosing chart [14] and broadly equivalent to a daily dose of 4 mg artesunate/kg (once daily for 3 days) and a single dose of 25 mg sulphadoxine/kg on day 0. Trial 1 used 50 mg artesunate tablets from Guilin Pharmaceutical, China and SP (500/25 mg tablets) from Roche, Switzerland. Trial 2 used Guilin artesunate and SP (500/25 mg tablets) from Durbin Pharmaceuticals. Trial 3 used blister packs (Artecospe® from Guilin Pharmaceutical Co. Ltd., China or Artesul from Zafa) containing SP tablets (500/25 mg) and 50 or 100 mg artesunate tablets. In Trials 2 and 3, drugs were provided by WHO via the Afghanistan National Malaria Control Program after quality control in a pre-qualified laboratory. Primaquine was not administered in any of the studies.
Patients receiving DP (trial 1 only) received Duo-Cotecxin® (Holleypharm, China) in which each co-formulated tablet contained 40 mg dihydroartemisinin and 320 mg piperaquine phosphate. The target total dose of 6/48 mg/kg was made up of three divided doses given on a daily basis. According to the body weight, individual doses were rounded to the nearest quarter tablet.
All doses of medicine were administered under the supervision of a qualified member of the staff designated by the principal investigator. The study patients were observed for 30 min after medicine administration for adverse reactions and/or vomiting. Patients who vomited during this observation period were re-treated with the same dose of medicine and observed for an additional 30 min. Patients vomiting again were to be given parenteral (and subsequently oral) therapy with quinine sulphate (10 mg base per kg body weight three times per day), along with once daily tetracycline (clindamycin in children) according to national malaria treatment guidelines, and withdrawn from further study.
Follow-up
Subjects were seen on days 0–3 inclusive and weekly to 56 days (trial 1) or 42 days (trials 2 and 3). Patients were also requested to attend if they felt unwell on any other day during follow-up. At each follow up visit a clinical assessment was carried out and the patient was asked about adverse events by the use of a standard symptom questionnaire. Thick and thin blood slides were examined and haemoglobin was measured. Other tests such as peripheral white blood cell count and urine examination were undertaken as indicated to rule out other conditions and investigate possible adverse effects of drugs. Patients were censored from the analysis if there was stated withdrawal of consent at any stage, persistent vomiting during the acute phase (necessitating parenteral treatment) or occurrence during the follow-up of concomitant disease that would interfere with a clear classification of the treatment outcome (including infection with P. vivax). Patients failing to attend follow-up visits received a visit at home and were asked to re-attend the centre for scheduled assessments. Transportation was provided for all follow-up visits for all subjects. All enrolled patients were given one long-lasting insecticide-treated bed net.
Patients with recurrence of P. falciparum had capillary blood collected on filter paper for PCR analysis and were treated with oral quinine and tetracycline (clindamycin in children) for 7 days with standard follow up.
Outcomes
The primary outcome was the proportion of patients with PCR-corrected adequate clinical and parasitological response (ACPR) at day 42 [15]. Secondary outcomes were the proportion of patients with PCR-corrected ACPR at day 28, crude or PCR-uncorrected ACPR, early treatment failure, parasite, fever and gametocyte clearance times, haemoglobin recovery and the rate and severity of adverse events.
Sample size
In trial 1 the aim was to examine whether DP was as effective as AS + SP via a non-inferiority design, given the relatively high predicted efficacy of AS + SP [16]; the non-inferiority margin (Δ) was set at 5 %. Sample size was 550 patients (275 per arm), calculated assuming a 95 % cure rate with AS + SP, a one-sided alpha of 0.05 and 80 % power.
Trials 2 and 3 were single arm monitoring studies and a sample size of 100 was chosen in each case consistent with WHO guidelines for therapeutic efficacy studies [15].
Randomisation and blinding (trial 1)
Patients were allocated to the two treatment arms based on a randomization list created using Stata 9.0 statistical software (StataCorp, College Station, TX) with a 1:1 allocation using a block size of 20 that was produced and held independently of the field teams by a statistician. The individual treatment allocations were kept in sequentially numbered, opaque, sealed envelopes and opened by the relevant field worker only after participant enrolment by the field team. Patients and clinical field workers were not blinded to the treatment arm after allocation. Laboratory workers assessing blood films and genotyping were not informed of the treatment arm.
Statistical methods
Data were entered into Microsoft Access or the WHO Study Information Sheet for calculation of baseline characteristics. Subsequent analyses were conducted using STATA (versions 10–12, Statcorp, USA) and GraphPad Prism (GraphPad, USA). The Student’s t test, Mann–Whitney U and Chi squared (or Fisher’s exact) tests were used for comparison of baseline variables between the two treatment arms of trial 1 and Wilson’s test was used for calculation of confidence intervals for ACPR.
Pharmacological studies
Day 7 blood samples were collected for drug measurements in Nangarhar and Kunar provinces in year 3 of trial 1, during the period September to December 2009. Approximately 100 µl capillary blood was collected onto Whatman 3MM filter papers and stored individually with silica gel for transportation to the Department of Clinical Pharmacology at MORU. Piperaquine concentrations (DP arm), adjusted for estimated sample volume, were determined by liquid chromatography and tandem mass spectrometry as described previously [17, 18]. Sulphadoxine concentrations (AS + SP studies) were determined by high performance liquid chromatography coupling with ultraviolet detector. This method is based on the method developed by Green et al. [19] with a slightly extended calibration range at both ends. Quality control samples (low, medium and high concentration) were analysed in triplicates within each batch to ensure accuracy and precision during routine drug measurements of clinical samples. Total accuracy and precision were below 7 % CV for all quality control samples. The lower limit of quantification was set to 3 ng/mL for piperaquine and 2 µg/mL for sulphadoxine.
Genotyping of baseline and recurrent infections
Blood samples were collected on filter paper (Whatman 3MM) at enrollment and at any visit where parasites were observed after day 7. Each filter paper was dried and stored individually in a plastic bag containing silica gel. All filter papers were subsequently transported to the Faculty of Tropical Medicine, Mahidol University. Parasite DNA from dried blood spots was extracted via the QIAmp DNA Mini kit using the standard protocol and stored at −20 °C until use. Nested PCR was performed to detect P. falciparum according to established methods. In order to differentiate a recrudescence from a reinfection, a genotype analysis was conducted based on the extensive genetic diversity in the polymorphic genes msp1, msp2 and glurp. The genotypic profiles of pre- and post-treatment strains were compared by standard methods [20].
PCR–RFLP and sequencing was undertaken for baseline samples in trial 1 examining pfdhr, pfdhps, pfcrt and pfmdr1 single nucleotide polymorphisms (SNPs) and pfmdr1 copy number assessment using previously described techniques [21, 22]; these data have already been published [23]. In trials 2 and 3 SNPs in pfdhr and pfdhps alone were examined and in trial 3 the artemisinin resistance marker K13 propeller [24] was sequenced using established techniques [25]. Heterozygous samples with evidence of both wild-type and mutant sequence were counted as mutants in overall calculations.
Ethical approval
All trials were approved by the Oxford Tropical Research Ethics Committee, Oxford University, UK (Refs. 032-07, 06-10 and 164-12) and the Institutional Review Board of the Afghanistan National Public Health Institute, Ministry of Public Health, Afghanistan. In addition trial 1 was approved by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University, Thailand and trials 2 and 3 were approved by the Ethical Review Committee of the WHO.
Results
Trial profile and progress
Trial flow. *In trial 1 the four cases lost to follow-up at d28 include one P. vivax infection at d28
Baseline characteristics
Baseline characteristics
Parameter | Study | |||
|---|---|---|---|---|
Trial 1 | Trial 2 | Trial 3 | ||
DP | AS + SP | AS + SP | AS + SP | |
Year | 2007–2010 | 2007–2010 | 2010–2011 | 2012–2014 |
No. of patients | 59 | 61 | 100 | 83 |
Location (%) | ||||
Jalalabad | 41 (69) | 42 (69) | 100 (100) | – |
Takhar | 6 (10) | 5 (8) | – | – |
Faryab | 1 (2) | 3 (5) | – | – |
Kunar | 11 (19) | 11 (18) | – | 83 (100) |
Age (years) (median, range) | 11 (2–52) | 13 (1–70) | 15.5 (3–55) | 18 (1–74) |
Gender male/female (ratio) | 43/16 (2.7) | 35/26 (1.3) | 60/40 (1.5) | 49/34 (1.4) |
Body weight (kg) (median, range) | 31 (8–87) | 35 (7.5-85) | 50 (10-72) | 49 (10–75) |
Median parasitaemia/µl (range) | 6760 (1220–90,000) | 7200 (900–62,160) | 4680 (1000–95,000) | 3220 (500–59,520) |
No. of patients with gametocytes (%) | 13 (22) | 29 (48) | 19 (19) | 42 (51) |
Mean axillary temp (°C) ± SD | 37.9 ± 1.1 | 37.9 ± 1.0 | 38.4 ± 0.8 | 38.4 ± 0.9 |
Mean hemoglobin (g/dl) ± SD | 11.2 ± 1.3 | 11.2 ± 1.4 | 11.50 ± 0.9 | 11.6 ± 1.9 |
Mean total drug dose (mg/kg) ± SD | ||||
Artemisinin derivative | 6.7 ± 1.2 (DHA) | 10.42 ± 1.9 (AS) | 10.5 ± 2.0 (AS) | 10.5 ± 2.4 (AS) |
Partner drug | 53.9 ± 9.3 (PIP) | 27.35 ± 11.9 (SUL) | 26.8 ± 5.0 (SUL) | 27.3 ± 6.1 (SUL) |
Outcomes
Efficacy at day 28, day 42 and day 56 (trial 1 only) expressed as percentage with ACPR
DP | AS + SP T1 | AS + SP T2 | AS + SP T3 | |
|---|---|---|---|---|
N (enrolled) | 59 | 61 | 100 | 83 |
d28 | ||||
Successful follow-up | 53 | 57 | 97 | 78 |
Reinfection | 0 | 0 | 0 | 0 |
Analysed | 53 | 57 | 97 | 78 |
Recrudescence | 0 | 0 | 1 | 0 |
ACPR % (95 % CI) | 100 (93.2–100) | 100 (93.7–100) | 99.0 (94.4–99.8) | 100 (95.3–100) |
d42 | ||||
Successful follow-up | 52 | 56 | 97 | 77 |
Recurrence: reinfection | 0 | 0 | 3 | 1 |
Recurrence: unknown genotype | 0 | 0 | 2 | 0 |
Analysed | 52 | 56 | 92 | 76 |
Recrudescence | 0 | 0 | 2 | 0 |
ACPR (95 % CI) | 100 (93.1–100) | 100 (93.6–100) | 97.8 (92.4–99.4) | 100 (95.2–100) |
d56 | ||||
Successful follow-up | 50 | 52 | ||
Recurrence: reinfection | 0 | 0 | ||
Recurrence: unknown genotype | 0 | 0 | ||
Analysed | 50 | 52 | ||
Recrudescence | 0 | 0 | ||
ACPR (95 % CI) | 100 (92.9–100) | 100 (93.1–100) | ||
Secondary analyses
Secondary outcomes in trial 1. Fever (a) and gametocyte (b) clearance and haemoglobin recovery (c) in the two arms of trial 1 (AS + SP vs. DHA-piperaquine)
Mean ± SD day 7 drug levels (adjusted for sample volume) for piperaquine were 98.5 ± 73.3 ng/mL (n = 20 patients), although in two cases levels were less than the limit of detection (0.75 ng/mL). There was a non-significant positive correlation between piperaquine concentration and the body weight-normalized total dose (Spearman r = 0.43, p = 0.06). Day 7 sulphadoxine levels were below the limit of detection (0.5 µg/mL) in nine of the 17 patients studied (spanning a range of ages), a finding that is challenging to correlate with the high measured efficacy.
Molecular data
Molecular data. The proportion of wild-type and mutant isolates is shown for five loci in each of dhfr and dhps (all trials) and the K13 propeller region (trial 3 only). a–c refer to the three separate trials undertaken, as indicated above each graph
Molecular findings
Study | Trial 1 | Trial 2 | Trial 3 | Total | ||||
|---|---|---|---|---|---|---|---|---|
Province | Jalalabad | Takhar | Faryab | Kunar | Jalalabad | Kunar | ||
DHFR | % with mutation | |||||||
A16 V | 32/0 | 3/0 | 2/0 | 7/0 | 71/0 | 49/0 | 164/0 | 0 |
N51I | 32/0 | 3/0 | 2/0 | 7/0 | 71/0 | 49/0 | 164/0 | 0 |
C59R | 2/30 | 0/3 | 0/2 | 0/7 | 5/66 | 2/47 | 9/155 | 94.5 |
S108 N | 0/32 | 0/3 | 0/2 | 0/7 | 0/71 | 0/49 | 0/164 | 100.0 |
I164L | 32/0 | 3/0 | 2/0 | 7/0 | 70/0 | 49/0 | 163/0 | 0 |
DHPS | ||||||||
S436A | 43/0 | 6/0 | 2/0 | 9/0 | 83/0 | 53/1 | 196/1 | 0.5 |
A437G | 38/3 | 6/0 | 1/1a | 4/4 | 80/3 | 50/4 | 179/15 | 7.7 |
K540E | 42/1 | 6/0 | 2/0 | 5/4 | 83/0 | 52/0 | 190/5 | 2.6 |
A581G | 40/3 | 6/0 | 1/1 | 5/4 | 34/0 | 47/7 | 133/15 | 10.1 |
A613S | 43/0 | 6/0 | 2/0 | 9/0 | 34/0 | 54/0 | 148/0 | 0 |
DHFR haplotype | Proportion (%) | |||||||
ANCNI | 2 | 5 | 2 | 9 | 5.5 | |||
ANRNI | 30 | 3 | 2 | 7 | 65 | 47 | 154 | 94.5 |
DHPS haplotype | ||||||||
SAKAA | 38 | 6 | 1 | 4 | 34 | 41 | 124 | 86.7 |
SAKGA | 6 | 6 | 4.2 | |||||
SGEGA | 1 | 4 | 5 | 3.5 | ||||
SGKAA | 1 | 3 | 4 | 2.8 | ||||
SGKGA | 1 | 1 | 2 | 1.4 | ||||
SSKGA | 1 | 1 | 0.7 | |||||
AAKAA | 1 | 1 | 0.7 | |||||
In trial 3, 58 out of 60 samples successfully sequenced at the K13-propeller locus were wild-type; the other samples had a Y493C and a S700L mutation. The patients carrying these isolates had negative blood smears on day 1 (24 h after the start of treatment).
Discussion
Prospective trials of the clinical efficacy of AS + SP, spanning the decade following its introduction as first-line recommended treatment for P. falciparum infection in Afghanistan, provide very reassuring evidence of maintained efficacy with rates of ACPR well over 95 % in all studies. Accompanying assessments of molecular markers explain these clinical responses. As in the rest of Asia and much of sub-Saharan Africa, two polymorphisms in dhfr (59R and 108 N) remain at or near fixation, but no other dhfr mutations are found in Afghanistan. A previous report generated concerns over the prevalence of the dhps triple mutation 437G/540E/581G in Nangarhar and Kunar provinces (the molecular data for trial 1 of this paper) [23] but the subsequent data indicate no evidence of this triple mutation in either province, and there was no increase in the individual mutations that make up the haplotype. In summary, there is no phenotypic or genotypic evidence of worsening resistance to SP a decade after the introduction of AS + SP in Afghanistan.
Compared to this, neighbouring countries show relatively more concerning resistance marker profiles. Surveys from Pakistan within the last decade show significant numbers of parasites mutated at DHPS 437G [26–28] as well as 540E and 581G (generally in mixed infections) [28]. Studies in central India [29, 30] and Iran [31, 32] also describe increasing mutations at 437G. However, AS + SP treatment of P. falciparum does not yet appear to have been significantly compromised by molecular changes in any of these locations. Only in northeast India is there evidence for a high prevalence of ‘quintuple’ mutation haplotypes based on these two genes [33] in association with reports of failure of AS + SP.
This is the first study to examine the K13 artemisinin resistance marker in Central Asia. Only two samples (less than 5 %) contained a mutation in the propeller domain; Y493C and S700L. Neither mutation has been previously reported, although a different mutation at 493, Y493H, is common and causally linked to artemisinin resistance in Cambodia [24, 34]. The patients carrying these isolates had rapid parasite clearance. Overall, the data indicate that isolates remain fully sensitive to artemisinins in Afghanistan.
The maintained efficacy of AS + SP, with no evidence of adaptive evolution in the dhps gene or increasing mutations in dhfr, is to some degree reminiscent of the return of in vitro mefloquine sensitivity following addition of artesunate to mefloquine at the Thai–Myanmar border in the 1990s [35]. While use of anti-malarials as ACT is predicted to protect against worsening resistance [36], it is not clear why AS + SP has retained its efficacy in Afghanistan over the course of 10 years despite a degree of pyrimethamine resistance at the outset, the lack of an available coformulation and clear evidence of worsening sensitivity in neighbouring countries. Factors that may have contributed to the maintained efficacy include restriction in terms of access to anti-malarials, a lack of fake or substandard anti-malarials and human factors, such as a tendency to complete prescribed courses.
Conclusions
AS + SP, the first-line treatment for falciparum malaria in Afghanistan, remains efficacious therapy for uncomplicated falciparum malaria, both in terms of initial parasite clearance and cure. Accompanying molecular data indicate a stable situation with regard to SP resistance, and suggest that AS + SP is likely to retain a high level of efficacy as treatment for P. falciparum for a substantial period of time as Afghanistan moves towards elimination.
Declarations
Authors’ contributions
GRA, SP, JT, AMD, NPJD, NJW and CJW designed the trials. GRA and FA were responsible for field work and sample collection. MI undertook molecular analyses. WH and JT undertook pharmacological analyses. GRA and CJW drafted the paper. All authors reviewed the manuscript. All authors read and approved the final manuscript.
Acknowledgements
GRA was supported by the Mahidol-Oxford Research Unit as a continuation of an MSc scholarship granted by the Thailand International Development and Cooperation Agency. The first trial was supported by the Li Ka Shing Foundation and was part of the Wellcome Trust Mahidol University-Oxford Tropical Medicine Research Programme supported by the Wellcome Trust of Great Britain. Trials 2 and 3 were funded by the Bill and Melinda Gates Foundation through WHO EMRO.
The investigators are grateful to the doctors, laboratory technicians and malaria workers in all sites in Afghanistan, the Afghanistan National Malaria and Leishmania Control Programme (NMLCP), the four provincial health directorates and the senior management of the Ministry of Public Health. They would also like to thank Pascal Ringwald and Hoda Atta for study support and critical review of the manuscript, the WHO EMRO malaria team for technical support and Dr. Sue Lee for statistical input. None of the funding bodies involved played a role in the design or analysis of the study.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ Affiliations
References
- Faulde MK, Hoffmann R, Fazilat KM, Hoerauf A. Malaria reemergence in northern Afghanistan. Emerg Infect Dis. 2007;13:1402–4.PubMed CentralView ArticlePubMedGoogle Scholar
- Dhir SL, Rahim A. Malaria and its control in Afghanistan (1950–1954). Indian J Malariol. 1957;11:73–126.PubMedGoogle Scholar
- Kolaczinski J, Graham K, Fahim A, Brooker S, Rowland M. Malaria control in Afghanistan: progress and challenges. Lancet. 2005;365:1506–12.View ArticlePubMedGoogle Scholar
- Brooker S, Leslie T, Kolaczinski K, Mohsen E, Mehboob N, Saleheen S, et al. Spatial epidemiology of Plasmodium vivax Afghanistan. Emerg Infect Dis. 2006;12:1600–2.PubMed CentralView ArticlePubMedGoogle Scholar
- Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J. 2011;10:378.PubMed CentralView ArticlePubMedGoogle Scholar
- Rab MA, Freeman TW, Durrani N, de Poerck D, Rowland MW. Resistance of Plasmodium falciparum malaria to chloroquine is widespread in eastern Afghanistan. Ann Trop Med Parasitol. 2001;95:41–6.View ArticlePubMedGoogle Scholar
- Durrani N, Leslie T, Rahim S, Graham K, Ahmad F, Rowland M. Efficacy of combination therapy with artesunate plus amodiaquine compared to monotherapy with chloroquine, amodiaquine or sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum in Afghanistan. Trop Med Int Health. 2005;10:521–9.View ArticlePubMedGoogle Scholar
- Rowland M, Durrani N, Hewitt S, Sondorp E. Resistance of falciparum malaria to chloroquine and sulfadoxine-pyrimethamine in Afghan refugee settlements in western Pakistan: surveys by the general health services using a simplified in vivo test. Trop Med Int Health. 1997;2:1049–56.View ArticlePubMedGoogle Scholar
- Howard N, Durrani N, Sanda S, Beshir K, Hallett R, Rowland M. Clinical trial of extended-dose chloroquine for treatment of resistant falciparum malaria among Afghan refugees in Pakistan. Malar J. 2011;10:171.PubMed CentralView ArticlePubMedGoogle Scholar
- Beshir K, Sutherland CJ, Merinopoulos I, Durrani N, Leslie T, Rowland M, et al. Amodiaquine resistance in Plasmodium falciparum malaria in Afghanistan is associated with the pfcrt SVMNT allele at codons 72 to 76. Antimicrob Agents Chemother. 2010;54:3714–6.PubMed CentralView ArticlePubMedGoogle Scholar
- Ezard N, Nellepalli P, Asha AW. Sulfadoxine-pyrimethamine remains efficacious against uncomplicated, Plasmodium falciparum malaria in north-eastern Afghanistan. Ann Trop Med Parasitol. 2004;98:85–8.View ArticlePubMedGoogle Scholar
- Faulde MK, Hoffmann R, Fazilat KM, Hoerauf A. Epidemiology of Plasmodium falciparum and P. vivax malaria endemic in northern Afghanistan. J Egypt Soc Parasitol. 2008;38:679–92.PubMedGoogle Scholar
- WHO. Severe and complicated malaria. Trans R Soc Trop Med Hyg. 2000;94(Suppl 1):1–90.Google Scholar
- WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006.Google Scholar
- WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009.Google Scholar
- Stepniewska K, White NJ. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J. 2006;5:127.PubMed CentralView ArticlePubMedGoogle Scholar
- Malm M, Lindegardh N, Bergqvist Y. Automated solid-phase extraction method for the determination of piperaquine in capillary blood applied onto sampling paper by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;809:43–9.View ArticlePubMedGoogle Scholar
- Lindegardh N, Annerberg A, White NJ, Day NP. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;862:227–36.View ArticlePubMedGoogle Scholar
- Green MD, Mount DL, Nettey H. High-performance liquid chromatographic assay for the simultaneous determination of sulfadoxine and pyrimethamine from whole blood dried onto filter paper. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;767:159–62.View ArticlePubMedGoogle Scholar
- Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, Brown KN, et al. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg. 1999;93:369–74.View ArticlePubMedGoogle Scholar
- Duraisingh MT, Curtis J, Warhurst DC. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol. 1998;89:1–8.View ArticlePubMedGoogle Scholar
- Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol. 2000;108:13–23.View ArticlePubMedGoogle Scholar
- Awab GR, Pukrittayakamee S, Jamornthanyawat N, Yamin F, Dondorp AM, Day NP, et al. Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan. Malar J. 2013;12:96.PubMed CentralView ArticlePubMedGoogle Scholar
- Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.View ArticlePubMedGoogle Scholar
- Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15:415–21.PubMed CentralView ArticlePubMedGoogle Scholar
- Khatoon L, Baliraine FN, Bonizzoni M, Malik SA, Yan G. Prevalence of antimalarial drug resistance mutations in Plasmodium vivax and P. falciparum from a malaria-endemic area of Pakistan. Am J Trop Med Hyg. 2009;81:525–8.PubMed CentralPubMedGoogle Scholar
- Ghanchi NK, Ursing J, Beg MA, Veiga MI, Jafri S, Martensson A. Prevalence of resistance associated polymorphisms in Plasmodium falciparum field isolates from southern Pakistan. Malar J. 2011;10:18.PubMed CentralView ArticlePubMedGoogle Scholar
- Khattak AA, Venkatesan M, Jacob CG, Artimovich EM, Nadeem MF, Nighat F, et al. A comprehensive survey of polymorphisms conferring anti-malarial resistance in Plasmodium falciparum across Pakistan. Malar J. 2013;12:300.PubMed CentralView ArticlePubMedGoogle Scholar
- Ahmed A, Bararia D, Vinayak S, Yameen M, Biswas S, Dev V, et al. Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with sulfadoxine-pyrimethamine resistance. Antimicrob Agents Chemother. 2004;48:879–89.PubMed CentralView ArticlePubMedGoogle Scholar
- Srivastava P, Ratha J, Shah NK, Mishra N, Anvikar AR, Sharma SK, et al. A clinical and molecular study of artesunate + sulphadoxine-pyrimethamine in three districts of central and eastern India. Malar J. 2013;12:247.PubMed CentralView ArticlePubMedGoogle Scholar
- Zakeri S, Farahani MS, Afsharpad M, Salehi M, Raeisi A, Djadid ND. High prevalence of the 437G mutation associated with sulfadoxine resistance among Plasmodium falciparum clinical isolates from Iran, three years after the introduction of sulfadoxine-pyrimethamine. Int J Infect Dis. 2010;14(Suppl 3):e123–8.View ArticlePubMedGoogle Scholar
- Rouhani M, Zakeri S, Pirahmadi S, Raeisi A, Djadid ND. High prevalence of pfdhfr-pfdhps triple mutations associated with anti-malarial drugs resistance in Plasmodium falciparum isolates seven years after the adoption of sulfadoxine-pyrimethamine in combination with artesunate as first-line treatment in Iran. Infect Genet Evol. 2015;1:183–9.View ArticleGoogle Scholar
- Mishra N, Kaitholia K, Srivastava B, Shah NK, Narayan JP, Dev V, et al. Declining efficacy of artesunate plus sulphadoxine-pyrimethamine in northeastern India. Malar J. 2014;13:284.PubMed CentralView ArticlePubMedGoogle Scholar
- Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015;347:428–31.PubMed CentralView ArticlePubMedGoogle Scholar
- Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet. 2000;356:297–302.View ArticlePubMedGoogle Scholar
- White NJ. Antimalarial drug resistance. J Clin Invest. 2004;113:1084–92.PubMed CentralView ArticlePubMedGoogle Scholar
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.